Research programme: cannabis extract therapeutics - Cannabis Science

Drug Profile

Research programme: cannabis extract therapeutics - Cannabis Science

Alternative Names: CS NEURO 1; CS-S/BCC-1; CS-TATI-1; Phytocannabinoid-based pharmaceutical products - Cannabis Science

Latest Information Update: 07 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cannabis Science
  • Developer Cannabis Science; Italian Institute for Health and Science on Ageing
  • Class Antineoplastics; Cannabinoids; Skin disorder therapies
  • Mechanism of Action Cannabinoid receptor modulators; Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome; Cancer; HIV infections; Kaposi's sarcoma; Pain; Post-traumatic stress disorders; Respiratory tract disorders; Skin cancer; Sleep disorders
  • Research Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder; Fibromyalgia; Neuropathic pain

Most Recent Events

  • 02 Feb 2018 Cannabis Science and Dana Farber Cancer Institute entered into a research collaboration agreement
  • 01 Dec 2017 Early research for Autistic-disorder is ongoing in USA (Cannabis Science Pipeline, December 2017)
  • 01 Dec 2017 Preclinical development in Adult-respiratory-distress-syndrome is ongoing in USA (PO, Lozenge) (Cannabis Science Pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top